Phosphorothioate 2′ deoxyribose oligomers as microbicides that inhibit human immunodeficiency virus type 1 (HIV-1) infection and block toll-like receptor 7 (TLR7) and TLR9 triggering by HIV-1

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 10, 2010, Pages 4064-4073

  Fraietta, Joseph A ^a   Mueller, Yvonne M ^a   Do, Duc H ^a   Holmes, Veronica M ^b   Howett, Mary K ^b   Lewis, Mark G ^c   Boesteanu, Alina C ^a   Alkan, Sefik S ^d   Katsikis, Peter D ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b DREXEL UNIVERSITY   (United States)

^c BIOQUAL INC   (United States)

^d Alkan Consulting LLC   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HYDROXYETHYLCELLULOSE; MICROBICIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PHOSPHOROTHIOATE 2' DEOXYRIBOSE OLIGOMER; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; OLIGONUCLEOTIDE; TLR9 PROTEIN, HUMAN;

ANIMAL CELL; ANTIBODY TITER; ANTIVIRAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CELL ADHESION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; EPITHELIUM CELL; EXPLANT; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; IN VITRO STUDY; LACTOBACILLUS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PH; PRIORITY JOURNAL; ROOM TEMPERATURE; SIMIAN IMMUNODEFICIENCY VIRUS; TARGET CELL; VAGINA; VAGINA FLORA; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS ISOLATION; CELL CULTURE; CELL LINE; CELL SURVIVAL; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM;

ANTI-INFECTIVE AGENTS; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-ALPHA; OLIGONUCLEOTIDES; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9;

EID: 77957352531     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00367-10     Document Type: Article

References (55)

1. Abel, K., Y. Wang, L. Fritts, E. Sanchez, E. Chung, P. Fitzgerald-Bocarsly, A. M. Krieg, and C. J. Miller. 2005. Deoxycytidyl- deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells. Clin. Diagn. Lab. Immunol. 12:606-621.
2. Anderson, D. J., J. A. Politch, L. D. Tucker, R. Fichorova, F. Haimovici, R. E. Tuomala, and K. H. Mayer. 1998. Quantitation of mediators of inflammation and immunity in genital tract secretions and their relevance to HIV type 1 transmission. AIDS Res. Hum. Retroviruses 14(Suppl. 1):S43-S49.
3. Balzarini, J., H. Pelemans, S. Aquaro, C. F. Perno, M. Witvrouw, D. Schols, E. De Clercq, and A. Karlsson. 1996. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol. Pharmacol. 50:394-401.
4. Beignon, A. S., K. McKenna, M. Skoberne, O. Manches, I. DaSilva, D. G. Kavanagh, M. Larsson, R. J. Gorelick, J. D. Lifson, and N. Bhardwaj. 2005. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J. Clin. Invest. 115:3265-3275.
5. Bjercke, S., H. Scott, L. R. Braathen, and E. Thorsby. 1983. HLA-DR-expressing Langerhans'-like cells in vaginal and cervical epithelium. Acta Obstet. Gynecol. Scand. 62:585-589.
6. Bollen, L. J., K. Blanchard, P. H. Kilmarx, S. Chaikummao, C. Connolly, P. Wasinrapee, N. Srivirojana, J. Achalapong, J. W. Tappero, and J. M. McNicholl. 2008. No increase in cervicovaginal proinflammatory cytokines after Carraguard use in a placebo-controlled randomized clinical trial. J. Acquir. Immune Defic. Syndr. 47:253-257.
7. Boyd, M. R., K. R. Gustafson, J. B. McMahon, R. H. Shoemaker, B. R. O'Keefe, T. Mori, R. J. Gulakowski, L. Wu, M. I. Rivera, C. M. Laurencot, M. J. Currens, J. H. Cardellina II, R. W. Buckheit, Jr., P. L. Nara, L. K. Pannell, R. C. Sowder II, and L. E. Henderson. 1997. Discovery of cyanovirin- N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob. Agents Chemother. 41:1521-1530.
8. Charneau, P., G. Mirambeau, P. Roux, S. Paulous, H. Buc, and F. Clavel. 1994. HIV-1 reverse transcription. A termination step at the center of the genome. J. Mol. Biol. 241:651-662.
9. Collins, K. B., B. K. Patterson, G. J. Naus, D. V. Landers, and P. Gupta. 2000. Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract. Nat. Med. 6:475-479.
10. Dhawan, D., and K. H. Mayer. 2006. Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection. J. Infect. Dis. 193:36-44.
11. Dimitonova, S. P., S. T. Danova, J. P. Serkedjieva, and B. V. Bakalov. 2007. Antimicrobial activity and protective properties of vaginal lactobacilli from healthy Bulgarian women. Anaerobe 13:178-184.
12. Equils, O., M. L. Schito, H. Karahashi, Z. Madak, A. Yarali, K. S. Michelsen, A. Sher, and M. Arditi. 2003. Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells: implications of simultaneous activation of TLRs on HIV replication. J. Immunol. 170:5159-5164. (Pubitemid 36554748)
13. Fauci, A. S. 2008. 25 years of HIV. Nature 453:289-290.
14. Girard, M., J. Mahoney, Q. Wei, E. van der Ryst, E. Muchmore, F. Barre- Sinoussi, and P. N. Fultz. 1998. Genital infection of female chimpanzees with human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 14:1357-1367.
15. Gorden, K. K., X. Qiu, J. J. Battiste, P. P. Wightman, J. P. Vasilakos, and S. S. Alkan. 2006. Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines. J. Immunol. 177:8164-8170.
16. Haas, T., J. Metzger, F. Schmitz, A. Heit, T. Muller, E. Latz, and H. Wagner. 2008. The DNA sugar backbone 2′ deoxyribose determines toll-like receptor 9 activation. Immunity 28:315-323. (Pubitemid 351335308)
17. Haas, T., F. Schmitz, A. Heit, and H. Wagner. 2009. Sequence independent interferon-alpha induction by multimerized phosphodiester DNA depends on spatial regulation of Toll-like receptor-9 activation in plasmacytoid dendritic cells. Immunology 126:290-298.
18. Haase, A. T. 2005. Perils at mucosal front lines for HIV and SIV and their hosts. Nat. Rev. Immunol. 5:783-792.
19. Herold, B. C., I. Scordi-Bello, N. Cheshenko, D. Marcellino, M. Dzuzelewski, F. Francois, R. Morin, V. M. Casullo, R. A. Anderson, C. Chany II, D. P. Waller, L. J. Zaneveld, and M. E. Klotman. 2002. Mandelic acid condensation polymer: novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry. J. Virol. 76:11236-11244.
20. Howett, M. K., E. B. Neely, N. D. Christensen, B. Wigdahl, F. C. Krebs, D. Malamud, S. D. Patrick, M. D. Pickel, P. A. Welsh, C. A. Reed, M. G. Ward, L. R. Budgeon, and J. W. Kreider. 1999. A broad-spectrum microbicide with virucidal activity against sexually transmitted viruses. Antimicrob. Agents Chemother. 43:314-321.
21. Iaccino, E., M. Schiavone, G. Fiume, I. Quinto, and G. Scala. 2008. The aftermath of the Merck's HIV vaccine trial. Retrovirology 5:56.
22. Khanna, K. V., K. J. Whaley, L. Zeitlin, T. R. Moench, K. Mehrazar, R. A. Cone, Z. Liao, J. E. Hildreth, T. E. Hoen, L. Shultz, and R. B. Markham. 2002. Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J. Clin. Invest. 109:205-211.
23. Kilmarx, P. H. 2009. Global epidemiology of HIV. Curr. Opin. HIV AIDS 4:240-246.
24. Klasse, P. J., R. J. Shattock, and J. P. Moore. 2006. Which topical microbicides for blocking HIV-1 transmission will work in the real world? PLoS Med. 3:e351.
25. Klinman, D. M., D. Tross, S. Klaschik, H. Shirota, and T. Sato. 2009. Therapeutic applications and mechanisms underlying the activity of immunosuppressive oligonucleotides. Ann. N. Y. Acad. Sci. 1175:80-88.
26. Lackman-Smith, C., C. Osterling, K. Luckenbaugh, M. Mankowski, B. Snyder, G. Lewis, J. Paull, A. Profy, R. G. Ptak, R. W. Buckheit, Jr., K. M. Watson, J. E. Cummins, Jr., and B. E. Sanders-Beer. 2008. Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob. Agents Chemother. 52:1768-1781.
27. Lederman, M. M., R. E. Offord, and O. Hartley. 2006. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat. Rev. Immunol. 6:371-382.
28. Lewis, M. G., S. Bellah, K. McKinnon, J. Yalley-Ogunro, P. M. Zack, W. R. Elkins, R. C. Desrosiers, and G. A. Eddy. 1994. Titration and characterization of two rhesus-derived SIVmac challenge stocks. AIDS Res. Hum. Retroviruses 10:213-220.
29. Li, Q., J. D. Estes, P. M. Schlievert, L. Duan, A. J. Brosnahan, P. J. Southern, C. S. Reilly, M. L. Peterson, N. Schultz-Darken, K. G. Brunner, K. R. Nephew, S. Pambuccian, J. D. Lifson, J. V. Carlis, and A. T. Haase. 2009. Glycerol monolaurate prevents mucosal SIV transmission. Nature 458:1034-1038.
30. Mandl, J. N., A. P. Barry, T. H. Vanderford, N. Kozyr, R. Chavan, S. Klucking, F. J. Barrat, R. L. Coffman, S. I. Staprans, and M. B. Feinberg. 2008. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat. Med. 14:1077-1087.
31. Meier, A., G. Alter, N. Frahm, H. Sidhu, B. Li, A. Bagchi, N. Teigen, H. Streeck, H. J. Stellbrink, J. Hellman, J. van Lunzen, and M. Altfeld. 2007. MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J. Virol. 81:8180-8191. (Pubitemid 47101504)
32. Miller, C. J., N. J. Alexander, S. Sutjipto, A. A. Lackner, A. Gettie, A. G. Hendrickx, L. J. Lowenstine, M. Jennings, and P. A. Marx. 1989. Genital mucosal transmission of simian immunodeficiency virus: animal model for heterosexual transmission of human immunodeficiency virus. J. Virol. 63:4277-4284.
33. Miller, C. J., Q. Li, K. Abel, E. Y. Kim, Z. M. Ma, S. Wietgrefe, L. La Franco-Scheuch, L. Compton, L. Duan, M. D. Shore, M. Zupancic, M. Busch, J. Carlis, S. Wolinsky, and A. T. Haase. 2005. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J. Virol. 79:9217-9227.
34. Miller, C. J., M. Marthas, J. Torten, N. J. Alexander, J. P. Moore, G. F. Doncel, and A. G. Hendrickx. 1994. Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia. J. Virol. 68:6391-6400.
35. O'Hanlon, D. E., B. R. Lanier, T. R. Moench, and R. A. Cone. 2010. Cervi- covaginal fluid and semen block the microbicidal activity of hydrogen peroxide produced by vaginal lactobacilli. BMC Infect. Dis. 10:120.
36. Patterson, B. K., A. Landay, J. Andersson, C. Brown, H. Behbahani, D. Jiyamapa, Z. Burki, D. Stanislawski, M. A. Czerniewski, and P. Garcia. 1998. Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am. J. Pathol. 153:481-490.
37. Patton, D. L., S. S. Thwin, A. Meier, T. M. Hooton, A. E. Stapleton, and D. A. Eschenbach. 2000. Epithelial cell layer thickness and immune cell populations in the normal human vagina at different stages of the menstrual cycle. Am. J. Obstet. Gynecol. 183:967-973.
38. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
39. Pearce-Pratt, R., and D. M. Phillips. 1996. Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1. Biol. Reprod. 54:173-182.
40. Piguet, V., and Q. Sattentau. 2004. Dangerous liaisons at the virological synapse. J. Clin. Invest. 114:605-610.
41. Politch, J. A., K. H. Mayer, and D. J. Anderson. 2009. Depletion of CD4+ T cells in semen during HIV infection and their restoration following antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 50:283-289.
42. Rabe, L. K., and S. L. Hillier. 2003. Optimization of media for detection of hydrogen peroxide production by Lactobacillus species. J. Clin. Microbiol. 41:3260-3264.
43. Schwartz, J. L., C. Mauck, J. J. Lai, M. D. Creinin, V. Brache, S. A. Ballagh, D. H. Weiner, S. L. Hillier, R. N. Fichorova, and M. Callahan. 2006. Fourteen- day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind phase I safety study. Contraception 74:133-140.
44. Sodora, D. L., A. Gettie, C. J. Miller, and P. A. Marx. 1998. Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Res. Hum. Retroviruses 14(Suppl. 1):S119-S123.
45. Spurbeck, R. R., and C. G. Arvidson. 2010. Lactobacillus jensenii surface-associated proteins inhibit Neisseria gonorrhoeae adherence to epithelial cells. Infect. Immun. 78:3103-3111.
46. Tan, G. T., A. Wickramasinghe, S. Verma, S. H. Hughes, J. M. Pezzuto, M. Baba, and P. Mohan. 1993. Sulfonic acid polymers are potent inhibitors of HIV-1 induced cytopathogenicity and the reverse transcriptases of both HIV-1 and HIV-2. Biochim. Biophys. Acta 1181:183-188.
47. Tien, D., R. L. Schnaare, F. Kang, G. Cohl, T. J. McCormick, T. R. Moench, G. Doncel, K. Watson, R. W. Buckheit, M. G. Lewis, J. Schwartz, K. Douville, and J. W. Romano. 2005. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res. Hum. Retroviruses 21:845-853.
48. Trifonova, R. T., G. F. Doncel, and R. N. Fichorova. 2009. Polyanionic microbicides modify Toll-like receptor-mediated cervicovaginal immune responses. Antimicrob. Agents Chemother. 53:1490-1500.
49. Wang, Y., K. Abel, K. Lantz, A. M. Krieg, M. B. McChesney, and C. J. Miller. 2005. The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J. Virol. 79:14355-14370.
50. Weber, J., A. Nunn, T. O'Connor, D. Jeffries, V. Kitchen, S. McCormack, J. Stott, N. Almond, A. Stone, and J. Darbyshire. 2001. 'Chemical condoms' for the prevention of HIV infection: evaluation of novel agents against SHIV(89.6PD) in vitro and in vivo. AIDS 15:1563-1568.
51. Wenzel, J., M. Uerlich, O. Haller, T. Bieber, and T. Tueting. 2005. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3- expressing lymphocytes into the skin following treatment with the TLR7- agonist imiquimod. J. Cutan. Pathol. 32:257-262.
52. Wolff, H., and D. J. Anderson. 1988. Immunohistologic characterization and quantitation of leukocyte subpopulations in human semen. Fertil. Steril. 49:497-504.
53. Zaneveld, L. J., D. P. Waller, R. A. Anderson, C. Chany II, W. F. Rencher, K. Feathergill, X. H. Diao, G. F. Doncel, B. Herold, and M. Cooper. 2002. Efficacy and safety of a new vaginal contraceptive antimicrobial formulation containing high molecular weight poly(sodium 4-styrenesulfonate). Biol. Reprod. 66:886-894.
54. Zeitlin, L., T. E. Hoen, S. L. Achilles, T. A. Hegarty, A. E. Jerse, J. W. Kreider, S. S. Olmsted, K. J. Whaley, R. A. Cone, and T. R. Moench. 2001. Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models. Sex. Transm. Dis. 28:417-423.
55. Zhu, T., H. Mo, N. Wang, D. S. Nam, Y. Cao, R. A. Koup, and D. D. Ho. 1993. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261:1179-1181.